2m 2m 2m 2m 2m 2m 2m
Fate Therapeutic (FATE)
NASDAQ
$3.02-$0.005 (-0.17%)
Price as of Jul 14, 2026 10:12 AM EDT- $352.0MMarket Cap
- 164.91%1-Year Change
- BiotechnologyIndustry
Fate Therapeutic (FATE)
$3.02-$0.005 (-0.17%)
FATE | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $3.02 | ||
Change | -$0.08 (-2.58%) | ||
Open | $3.08 | ||
High | $3.23 | ||
Low | $2.80 | ||
Previous Close | $3.10 | ||
Volume | 6,046,416 | ||
30-Day Average Volume | 5,130,020 | ||
1-Week Change | 1.00% | ||
1-Month Change | 46.60% | ||
1-Year Change | 164.91% | ||
3-Year Change | -38.62% | ||
5-Year Change | -96.29% | ||
Fundamentals | |||
Shares Outstanding | 116.6M | ||
Total Assets | $284.9M | ||
Market Cap | $352.0M | ||
Enterprise Value | $312.4M | ||
Period: QTR TTM FY | |||
Revenue | $1.3M | ||
Net Income | -$31.2M | ||
Free Cash Flow | -$31.1M | ||
EBIT | -$31.2M | ||
EBITDA | -$28.3M | ||
Net Working Capital | $148.8M | ||
EPS | -$0.26 | ||
Enterprise Value/EBITDA | -11 | ||
Enterprise Value/Revenue | 241 | ||
P/B | 2 | ||
P/E | -12 | ||
PEG | -3 | ||
Price/Free Cash Flow | -11 | ||
Price/Operating Cash Flow | -11 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue